This Chinese pharma filed for an IPO last September. Seven months and a $283M investment later, they are back at the HKEX

A storied Chinese pharma player is aiming for a second shot at joining some pre-revenue biotechs on the Hong Kong Stock Exchange, in an IPO that could fetch anywhere between $500 million and $1 billion.